Inovio Pharmaceuticals, Inc. (INO) Stock Rating Reaffirmed by HC Wainwright
Inovio Pharmaceuticals, Inc. (NASDAQ:INO)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a note issued to investors on Thursday. They presently have a $13.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price objective suggests a potential upside of 174.26% from the stock’s current price.
Other analysts also recently issued reports about the company. BidaskClub upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, September 9th. Maxim Group set a $12.00 price objective on Inovio Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 9th. Royal Bank of Canada assumed coverage on Inovio Pharmaceuticals in a research report on Wednesday, October 18th. They issued an “outperform” rating and a $11.00 price objective on the stock. Zacks Investment Research downgraded Inovio Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. Finally, Aegis restated a “buy” rating and issued a $14.00 price objective on shares of Inovio Pharmaceuticals in a research report on Tuesday, July 18th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $19.16.
Inovio Pharmaceuticals (INO) traded up $0.31 on Thursday, reaching $4.74. The company’s stock had a trading volume of 1,969,800 shares, compared to its average volume of 1,281,650. Inovio Pharmaceuticals has a one year low of $4.40 and a one year high of $9.86.
Inovio Pharmaceuticals (NASDAQ:INO) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.15). The firm had revenue of $2.60 million for the quarter, compared to analysts’ expectations of $10.27 million. Inovio Pharmaceuticals had a negative return on equity of 72.19% and a negative net margin of 221.55%. The firm’s revenue for the quarter was down 79.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.28) earnings per share. equities analysts predict that Inovio Pharmaceuticals will post -0.88 EPS for the current year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in INO. Wasatch Advisors Inc. lifted its position in Inovio Pharmaceuticals by 43.6% during the second quarter. Wasatch Advisors Inc. now owns 2,610,818 shares of the biopharmaceutical company’s stock worth $20,469,000 after buying an additional 793,306 shares during the period. Vanguard Group Inc. lifted its position in Inovio Pharmaceuticals by 7.9% during the first quarter. Vanguard Group Inc. now owns 3,098,055 shares of the biopharmaceutical company’s stock worth $20,510,000 after buying an additional 226,861 shares during the period. Candriam Luxembourg S.C.A. purchased a new position in Inovio Pharmaceuticals during the second quarter worth about $1,411,000. GSA Capital Partners LLP purchased a new position in Inovio Pharmaceuticals during the second quarter worth about $1,035,000. Finally, Virtu KCG Holdings LLC purchased a new position in Inovio Pharmaceuticals during the second quarter worth about $556,000. Hedge funds and other institutional investors own 25.04% of the company’s stock.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.